en · de · es
selank-notes.peptides3081.com › Blog › Background And Peptide Identity — Common Mistakes

Background And Peptide Identity — Common Mistakes

By Editorial Desk · published 2025-08-15 · last reviewed 2025-09-29 · Blog

Tuftsin analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Proposed Mechanisms and Research Endpoints

Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.

Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.

Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.

Selank at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptideModeled on tuftsin
Amino acid sequenceThr-Lys-Pro-Arg-Pro-Gly-ProSeven residues
Approximate molecular massAround 750 DaDepends on counter-ion and hydration
Common formsLyophilized powderAlso described as aqueous solution
Primary origin of researchRussian laboratoriesMid-1990s onward

Background and Molecular Identity

Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.

Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.

Related pages on this site

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Reference notes

=== Children === Babies are at increased risk of developing iron deficiency anemia due to their rapid growth. Their need for iron is greater than they are getting in their diet. Babies are born with iron stores; however, these iron stores typically run out by 4–6 months of age. In addition, infants who are given cow's milk too early can develop anemia due to gastrointestinal blood loss. Children who are at risk for iron-deficiency anemia include:

Although American rocket pioneer Robert H. Goddard developed, patented, and flew small liquid-propellant rockets as early as 1914, the United States was the only one of the three major allied World War II powers to not have its own rocket program, until Von Braun and his engineers were expatriated from Nazi Germany in 1945. The US acquired a large number of V-2 rockets and recruited von Braun and most of his engineering team in Operation Paperclip. The team was sent to the Army's White Sands Proving Ground in New Mexico, in 1945. They set about assembling the captured V-2s and began a program of launching them and instructing American engineers in their operation. These tests led to the first photos of Earth from space, and the first two-stage rocket, the WAC Corporal-V-2 combination, in 1949. The German rocket team was moved from Fort Bliss to the Army's new Redstone Arsenal, located in Huntsville, Alabama, in 1950. From here, von Braun and his team developed the Army's first operational medium-range ballistic missile, the Redstone rocket, derivatives of which launched both America's first satellite, and the first piloted Mercury space missions. It became the basis for both the Jupiter and Saturn family of rockets.

The western regions of Pakistan became a part of the Achaemenid Empire around 517 BCE. In 326 BCE, Alexander the Great conquered the region by defeating various local rulers, most notably, the King Porus, at Jhelum. Among the major powers that ruled the region were the Mauryas (322–185 BCE), during which Ashoka the Great extended the empire. The Indo-Greek Kingdom founded by Demetrius of Bactria (180–165 BCE) included Gandhara and Punjab and reached its greatest extent under Menander (165–150 BCE), allowing the Greco-Buddhist culture in the region to prosper. Taxila had one of the earliest universities and centres of higher education in the world, which was established during the late Vedic period in the 6th century BCE. The ancient university was documented by the invading forces of Alexander the Great and recorded by Chinese pilgrims in the 4th or 5th century CE. At its zenith, the Rai dynasty (489–632 CE) ruled Sindh and the surrounding territories.

=== Obesity === Obesity is a global epidemic health problem and has received considerable attention as a major public hazard. Obesity is a chronic pathological and costly disease of abnormal or excessive fat accumulation in the body. Studies indicate that 5-HT2C receptor activation will regulate appetite and food consumption, most likely by promoting satiety through appetite suppression by activation of 5-HT2C. Consequently, selective agents with high affinity for this receptor over 5-HT2B and 5-HT22A are being developed for the treatment of obesity.

Sources: en.wikipedia.org

Notes from published material

One possible explanation is that freezing causes the loss of hydroxyl groups on the Alum, destabilizing its association with the antigen. Another explanation is the agglomeration of adjuvant-antigen complexes, forming larger particles of lower surface area. In either case, there are a number of cryoprotectants such as glycerine that can be added to the typical vial of aluminum liquid suspension vaccine to reduce the loss of potency. Some scientists are also working on making Alum-containg vaccines suitable for freeze-drying. Freeze-dried vaccines exist as a stable dry powder containing nothing to freeze.

The International Mass Spectrometry Foundation (IMSF) is a non-profit scientific organization in the field of mass spectrometry. It operates the International Mass Spectrometry Society, which consists of 37 member societies and sponsors the International Mass Spectrometry Conference that is held once every two years.

== Education == Wigler graduated from Princeton University in 1970, majoring in mathematics, and in 1978 received his PhD from Columbia University in microbiology, and has spent the remainder of his career at Cold Spring Harbor Laboratory (CSHL).

=== 116th Congress (2019–2021) === In March 2019, Kennedy introduced the Holding Foreign Companies Accountable Act, which Trump signed into law on December 18, 2020. The law prohibits any company from listing on an American stock exchange if it refuses to allow the Public Company Accounting Oversight Board to audit its annual private audit for three consecutive years. It also requires companies to disclose whether they are owned by a foreign government. In 2019, Kennedy again introduced a bill to extend the National Flood Insurance Program. It extended the program through June 14, 2019, rather than lapsing on May 31. The bill passed the Senate on May 23, 2019, and was signed into law.

The chief minister of Tamil Nadu is the head of government of the Indian state of Tamil Nadu. In accordance with the Constitution of India, the governor is a state's de jure head, while the de facto authority rests with the chief minister. Following elections to the Tamil Nadu Legislative Assembly, the state's governor usually invites the party (or coalition) with the majority of seats in the assembly to form the government. The governor appoints the chief minister, whose council of ministers are collectively responsible to the assembly. Given that the chief minister has the confidence of the assembly, the chief minister's term is for five years and is subject to no term limits. Since 1950, Tamil Nadu has had 14 chief ministers. The first four chief ministers belonged to the Indian National Congress, of which K. Kamaraj held the post for the longest, for more than nine years. With the rise of Dravidian parties in the state, C. N. Annadurai of the Dravida Munnetra Kazhagam (DMK) became the first non-Congress chief minister in 1969. Annadurai was from the Tamil film industry, and since his tenure, a significant number of the state's chief ministers have hailed from the industry. M. Karunanidhi of the DMK succeeded Annadurai, and was the longest-serving chief minister, holding the office for nearly nineteen years across five tenures. M. G. Ramachandran of the All India Anna Dravida Munnetra Kazhagam (AIADMK) took office in 1977 and served for nearly a decade across three terms. In 1988, V. N.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is Selank?

Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.

Where was Selank developed?

It originates from research in Russia, associated with the Institute of Molecular Genetics of the Russian Academy of Sciences. The first descriptions date to the mid-1990s. Most published studies come from Russian laboratories.

Is Selank found in nature?

No, Selank itself does not occur naturally. Its backbone is based on tuftsin, which is produced in the body, but the seven-residue version is a synthetic construct. It is supplied as a manufactured peptide.

How is Selank administered in studies?

Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.

Network